Jagsonpal Pharmaceuticals Consummates Group Pharma Wellness Portfolio Acquisition

Jagsonpal Pharmaceuticals Ltd. has successfully consummated the acquisition of Group Pharmaceuticals Limited's Wellness Portfolio, effective October 01, 2026. This strategic move, following the fulfillment of conditions precedent under the Business Transfer Agreement (BTA), aims to bolster Jagsonpal's existing Rx franchise by adding a complementary portfolio. The acquisition is expected to create cross-selling opportunities through an expanded field force and doctor network, contributing to the company's ₹500 Cr ambition and enhancing overall productivity. This marks Jagsonpal's third acquisition in four years, building on previous integrations of Yash Pharma and Aequitas Healthcare, and is part of a strategy to build scale, expand market access, and create long-term shareholder value.